Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint
Executive Summary
Results from an Amgen trial showing that anemia therapy Aranesp has a neutral impact on survival in cancer patients receiving chemotherapy could assuage concerns over the safety profile of erythropoiesis-stimulating agents at high doses
You may also be interested in...
Silver Lining In Aranesp Trial Outshines Its Two Failed Endpoints
Unlike previous trials, TREAT did not show a statistically significant adverse effect on all-cause mortality or cardiovascular morbidity when patients were treated to a hemoglobin target of 13 g/dL.
Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting
Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee
Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting
Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee